Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Apellis Pharmaceuticals And Sobi Announce Positive One-Year Results From Phase 2 NOBLE Study Of Pegcetacoplan For Post-Transplant Recurrence Of C3 Glomerulopathy (C3G) And IC-MPGN

Author: Benzinga Newsdesk | May 24, 2024 10:01am

Rapid reduction in disease activity seen at 12 weeks was sustained at one year
55% of patients showed zero C3c staining intensity, indicating that C3c deposits were cleared
Highlighted as late-breaking oral presentation at the European Renal Association (ERA) Congress

Posted In: APLS